Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2022, 4(6); doi: 10.25236/IJFM.2022.040609.

Research progress of EGCG in the treatment of Alzheimer's disease


Lin Meng1, Changxing Liu2, Lili Yuan2, Xiang Chang3

Corresponding Author:
Xiang Chang

1Cerebrovascular Disease of Integrated Traditional Chinese and Western Medicine, Shaanxi University of Traditional Chinese Medicine, Xi’ an, China

2Cerebrovascular Disease, Shaanxi University of Traditional Chinese Medicine, Xi’an, China

3Xi'an Traditional Chinese Medicine Hospital, Xi' an, Shaanxi, China


Alzheimer's disease (AD) is a degenerative disease of the nervous system. Mainly presenting with neuropsychiatric symptoms such as progressive memory impairment, cognitive dysfunction, personality changes, and language disorders [1]. Also known as senile dementia, it is the leading cause of dementia in the elderly [2]. Involved in 60-80% of all reports of dementia [3]. As the global population ages, AD prevalence and mortality rates increase. It seriously affects the quality of life of the elderly and brings a heavy economic burden and severe social problems. The tea polyphenol epigallocatechin gallate (EGCG) has preventive and therapeutic effects on Alzheimer's disease by inhibiting the amyloid formation and aggregation, antioxidant, anti-inflammatory, metal chelating, binding cholinesterase, thereby reducing the degradation of acetylcholine, and repairing mitochondrial dysfunction. This article reviews the research on the mechanism of EGCG action on Alzheimer's disease.


EGCG; Alzheimer's disease; amyloid antioxidant; anti-inflammatory

Cite This Paper

Lin Meng, Changxing Liu, Lili Yuan, Xiang Chang. Research progress of EGCG in the treatment of Alzheimer's disease. International Journal of Frontiers in Medicine (2022), Vol. 4, Issue 6: 48-56. https://doi.org/10.25236/IJFM.2022.040609.


[1] 2020 Alzheimer's disease facts and figures. Alzheimer's Dement. 2020;10.1002/alz.12068.

[2] Goldfarb D, Sheard S, Shaughnessy L, Atri A. Disclosure of Alzheimer's Disease and Dementia: Patient- and Care Partner-Centric Decision-Making and Communication. J Clin Psychiatry. 2019; 80(2): MS18002BR1C. 

[3] Zhu Z, Liu Y, Li X, et al. GPNMB mitigates Alzheimer's disease and enhances autophagy via suppressing the mTOR signal. Neurosci Lett. 2021;136300. 

[4] World Health Organization WHO - The top 10 causes of death. Available online: http://www.who.int/ en/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on Jan 6, 2021).

[5] Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018; 25(1): 59-70. doi:10.1111/ene. 13439

[6] Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer's disease. Nat Neurosci. 2020; 23(10): 1183-1193. 

[7] Gonçalves PB, Sodero ACR, Cordeiro Y. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Biomolecules. 2021; 11(5): 767.

[8] Pervin M, Unno K, Takagaki A, Isemura M, Nakamura Y. Function of Green Tea Catechins in the Brain: Epigallocatechin Gallate and its Metabolites. Int J Mol Sci. 2019; 20(15): 3630. 

[9] ZENG Lu, ZHANG Shuai, AI Jing. Research Progress of Epigallocatechin Gallate [J]. Journal of Neuropharmacology, 2021, 11(1): 38-56.

[10] Salminen A, Kaarniranta K, Kauppinen A, et al. Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome. Prog Neurobiol. 2013; 106-107: 33-54.

[11] LA FERIA E, GREEN I, ODDO S.Inlxacellular amyloid-β in Alzheimer's disease [J]. Nature RevNeurosci, 2007, 8(7): 499-509.

[12] Yu H, Wu J. Amyloid-β: A double agent in Alzheimer's disease?. Biomed Pharmacother. 2021; 139: 111575.

[13] Alastair F, Alshammari MA, Alasmari AF, et al. Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism. Biomed Res Int. 2018; 2018: 3087475.

[14] Payne A, Nahashon S, Taka E, et al. Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age. Biomolecules. 2022; 12(3): 371.

[15] Rezai-Zadeh K, Shytle D, Sun N, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005; 25(38): 8807-8814.

[16] Fernandes L, Cardim-Pires TR, Fogel D, Palhano FL. Green Tea Polyphenol Epigallocatechin-Gallate in Amyloid Aggregation and Neurodegenerative Diseases. Front Neurosci. 2021; 15: 718188.

[17] Lee J W, Lee Y K, Ban J O, et al. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice[J]. J Nutr, 2009, 139 (10):1987-93.

[18] Zhang ZX, Li YB, Zhao RP. Epigallocatechin Gallate Attenuates β-Amyloid Generation and Oxidative Stress Involvement of PPARγ in N2a/APP695 Cells. Neurochem Res. 2017; 42(2): 468-480. 

[19] Polito CA, Cai ZY, Shi YL, et al. Association of Tea Consumption with Risk of Alzheimer's Disease and Anti-Beta-Amyloid Effects of Tea. Nutrients. 2018; 10(5): 655.

[20] Gonçalves PB, Sodero ACR, Cordeiro Y. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Biomolecules. 2021; 11(5): 767.

[21] Rezai-Zadeh K, Arendash GW, Hou H, et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 2008; 1214: 177-187.

[22] Bao J, Liu W, Zhou HY, et al. Epigallocatechin-3-gallate Alleviates Cognitive Deficits in APP/PS1 Mice. Curr Med Sci. 2020; 40(1): 18-27. 

[23] Lee SB, Choi EH, Jeong KH, Kim KS, Shim SM, Kim GH. Effect of catechins and high-temperature-processed green tea extract on scavenging reactive oxygen species and preventing Aβ1-42 fibrils' formation in brain microvascular endothelium. Nutr Neurosci. 2020; 23(5): 363-373.

[24] Wang SH, Liu FF, Dong XY, Sun Y. Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (-)-epigallocatechin-3-gallate. J Phys Chem B. 2010;114(35): 11576-11583. 

[25] Salim S El-Amouri, Hong Zhu, Jin Yu, et al. Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease [J]. Am J Pathol, 2008, 172 (5): 1342-1354. 

[26] Xiang Chang, Cui-ping Rong, Yun-bo Chen, et al. (-)-epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression [J]. Experimental Cell Research, 2015, 334 (1): 136-145.

[27] Chengyan Sun, Ning JIA, Kun Han. Effects of epigallocatechin gallate on cognitive function and hippocampal autophagy in APP/PS1 transgenic mice [J]. Chinese Pharmacological Bulletin, 2020, 36 (04): 539-543.

[28] Drummond E, Pires G, MacMurray C, et al. Phosphorylated tau interactome in the human Alzheimer's disease brain. Brain. 2020; 143(9): 2803-2817.

[29] Guo Y, Zhao Y, Nan Y, et al. (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease [J]. Neuroreport, 2017, 28 (10): 590-597.

[30] Nan S, Wang P, Zhang Y, Fan J. Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats. Drug Des Devel Ther. 2021; 15: 2013-2024.

[31] Lin CL, Chen T F, Chiu M J, et al. Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation[J]. Neurobiol Aging, 2009, 30 (1): 81-92.

[32] Xu Y H, Chen Y, Zhang P, et al. Structure of a protein phosphatase 2A holoenzyme: Insights into B55-mediated Tau dephosphorylation [J]. Molecular Cell, 2008, 31(6): 873-85.

[33] Chesser AS, Ganeshan V, Yang J, et al. Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. Nutr Neurosci. 2016; 19(1): 21-31. 

[34] Uttara B, Singh AV, Zamboni P, et al. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options [J]. Curr Neuropharmacol, 2009, 7 (1): 65-74.

[35] Butterfield D A, Castagna A, Lauderback CM, et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death[J]. Neurobiol Aging, 2002, 23 (5): 655-64.

[36] Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons[J]. Neurobiol Dis, 2002, 10 (3): 279-88.

[37] Plascencia-Villa G, Perry G. Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. Antioxid Redox Signal. 2021;34(8):591-610.

[38] Teng Y, Zhao J, Ding L, et al. Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein. Molecules. 2019;24(16):2940. 

[39] Gyanendra Singh, Riddhi Thaker, Anupama Sharma, et al. Therapeutic effects of biochanin a, phloretin, and epigallocatechin-3-gallate in reducing oxidative stress in arsenic-intoxicated mice [J]. J Biochem Mol Toxicol, 2021, 28(16): 20517-20536. 

[40] Smith RE, Tran K, Smith CC, McDonald M, Shejwalkar P, Hara K. The Role of the Nrf2/ARE Antioxidant System in Preventing Cardiovascular Diseases. Diseases. 2016; 4(4): 34.

[41] Wang J, Jia R, Celi P, et al. Green tea polyphenol epigallocatechin-3-gallate improves the antioxidant capacity of eggs. Food Funct. 2020;11(1): 534-543.

[42] Bostancıklıoğlu M. An update on the interactions between Alzheimer's disease, autophagy and inflammation. Gene. 2019; 705: 157-166.

[43] Walker KA, Ficek BN, Westbrook R. Understanding the Role of Systemic Inflammation in Alzheimer's Disease. ACS Chem Neurosci. 2019; 10(8): 3340-3342. 

[44] WALKER K A, FICEK BN, WESTBROOK R. Understanding the role of systemic inflammation in Alzheimer's disease [J]. ACS Chemical Neuroscience, 2019, 10(8): 3340-3342.

[45] Sheng-Wei Lai, Jia-Hong Chen, Hsiao-Yun Lin, et al.Regulatory effects of neuroinflammatory responses through brain-derived neurotrophic factor signaling in microglial cells [J]. Molecular Neurobiology, 2018, 55 (9): 7487-7499. 

[46] Zhong X, Liu M, Yao W, et al. Epigallocatechin-3-Gallate Attenuates Microglial Inflammation and Neurotoxicity by Suppressing the Activation of Canonical and Noncanonical Inflammasome via TLR4/NF-κB Pathway. Mol Nutr Food Res. 2019; 63(21): e1801230.

[47] Peairs A, Dai R, Gan L, et al. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/LPR mouse mesangial cells. Cell Mol Immunol. 2010; 7(2): 123-132.

[48] Cheng CY, Barro L, Tsai ST, et al. Epigallocatechin-3-Gallate-Loaded Liposomes Favor Anti-Inflammation of Microglia Cells and Promote Neuroprotection. Int J Mol Sci. 2021; 22(6): 3037.

[49] Wang L, Yin YL, Liu XZ, et al. Current understanding of metal ions in the pathogenesis of Alzheimer's disease. Transl Neurodegener. 2020; 9: 10. 

[50] Savelieff MG, Lee S, Liu Y, Lim MH. Untangling amyloid-β, tau, and metals in Alzheimer's disease. ACS Chem Biol. 2013; 8(5): 856-865. 

[51] Zwolak I. Epigallocatechin Gallate for Management of Heavy Metal-Induced Oxidative Stress: Mechanisms of Action, Efficacy, and Concerns. Int J Mol Sci. 2021;22(8):4027.

[52] Mandel SA, Weinreb O, Amit T, Youdim MB. Molecular mechanisms of the neuroprotective/ neurorescue action of multi-target green tea polyphenols. Front Biosci (Schol Ed). 2012; 4(2): 581-598.

[53] Zhang B, Cheng XR, da Silva IS, et al. Electroanalysis of the interaction between (-)-epigallocatechin-3-gallate (EGCG) and amyloid-β in the presence of copper. Metallomics. 2013; 5(3): 259-264.

[54] Singh NA, Mandal AKA, Khan ZA. Inhibition of Al(III)-Induced Aβ42 Fibrillation and Reduction of Neurotoxicity by Epigallocatechin-3-Gallate Nanoparticles. J Biomed Nanotechnol. 2018; 14(6): 1147-1158.

[55] Hyung S J, Detoma A S, Brender J R, et al. Insights into anti-amyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-beta species[J]. Proc Natl Acad Sci U S A, 2013, 110 (10): 3743-8.

[56] Singh NA, Mandal AK, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J. 2016; 15(1): 60.

[57] Sharma C, Kim S, Nam Y, Jung UJ, Kim SR. Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer's Disease. Int J Mol Sci. 2021; 22(9): 4850.

[58] Camilleri A, Zarb C, Caruana M, et al. Mitochondrial membrane permeabilization by amyloid aggregates and protection by polyphenols. Biochim Biophys Acta. 2013; 1828(11): 2532-2543.

[59] Abyadeh M, Gupta V, Chitranshi N, et al. Mitochondrial dysfunction in Alzheimer's disease - a proteomics perspective. Expert Rev Proteomics. 2021; 18(4): 295-304.

[60] Weidling IW, Swerdlow RH. Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis. Exp Neurol. 2020; 330: 113321. 

[61] Dragicevic N, Smith A, Lin X, et al. Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. J Alzheimers Dis. 2011; 26(3): 507-521.

[62] Chen Y, Chen J, Sun X, et al. Evaluation of the neuroprotective effect of EGCG: a potential mechanism of mitochondrial dysfunction and mitochondrial dynamics after subarachnoid hemorrhage. Food Funct. 2018;9(12):6349-6359.

[63] Liu HW, Chan YC, Wang MF, et al.Dietary (-)-Epigallocatechin-3-gallate Supplementation Counteracts Aging-Associated Skeletal Muscle Insulin Resistance and Fatty Liver in Senescence-Accelerated Mouse. J Agric Food Chem. 2015;63(38):8407-8417.

[64] Valenti D, de Bari L, de Rasmo D, et al. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model. Biochim Biophys Acta. 2016;1862(6):1093-1104.

[65] Ayyalasomayajula N, Bandaru LJM, Chetty CS, et al. Mitochondria-Mediated Moderation of Apoptosis by EGCG in Cytotoxic Neuronal Cells Induced by Lead (Pb) and Amyloid Peptides [published online ahead of print, 2021 Nov 19]. Biol Trace Elem Res. 2021;10.1007/s12011-021-02959-w.

[66] Colangelo C, Shichkova P, Keller D, Markram H, Ramaswamy S. Cellular, Synaptic and Network Effects of Acetylcholine in the Neocortex. Front Neural Circuits. 2019; 13: 24.

[67] Greig N H, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase[J]. Curr Med Res Opin, 2001, 17 (3): 159-65.

[68] Ali B, Jamal QM, Shams S, et al. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. CNS Neurol Disord Drug Targets. 2016; 15(5): 624-628.

[69] Okello EJ, Mather J. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease. Nutrients. 2020; 12(4): 1090. 

[70] Mori T, Koyama N, Tan J, et al. Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice [J]. J Biol Chem, 2019, 294 (8): 2714-2731.

[71] Giunta B, Hou H, Zhu Y, et al. Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice [J]. Neurosci Lett, 2010, 471 (3): 134-8.

[72] Cano A, Ettcheto M, Chang JH, et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. J Control Release. 2019; 301: 62-75. 

[73] Smith A, Giunta B, Bickford P C, et al. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease[J]. Int J Pharm, 2010, 389 (1-2): 207-12.

[74] Yang Peng, Guo Qian, Xu Shu-ting, et al. Constructing Brain Aβ-Targeting Nanoparticles Loaded with EGCG for Treating Alzheimer's Disease in Mice[J]. Journal of Sichuan University (Medical Science Edition), 2021, 52 (04): 605-611.

[75] Hey JR, Arora S, Zhang H, et al. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells. Nutrients. 2018;10(11):1644.

[76] Xu J, Tu Y, Wang Y, et al. Prodrug of epigallocatechin-3-gallate alleviates choroidal neovascularization via down-regulating HIF-1α/VEGF/VEGFR2 pathway and M1 type macrophage/ microglia polarization. Biomed Pharmacother. 2020; 121: 109606.